Skip to content
The Nexus
DossierENTITY

IBRX

Coverage of IBRX in the Nexus archive.

Earliest in view: Aug 4 · 11:44 UTCMost recent: Aug 4 · 11:44 UTC
Co-mentioned in this coverage
ImmunityBio, Inc.organization1San Diegoplace1Automated Insightsorganization1Zacks Investment Researchorganization1immunotherapytopic1
Recent coverage
  • BUSINESSAug 4 · 11:44 UTCWTOP DC
    ImmunityBio: Q2 Earnings Snapshot

    ImmunityBio, Inc. reported a second-quarter loss of $230.4 million, or 22 cents per share, with adjusted losses of 8 cents per share. The company generated $51.2 million in revenue during the period.

IBRX · Dossier · The Nexus